Allowable warm ischemic time to tracheal extraction for allotransplantation of cryopreserved trachea

Optimization of Chondrocyte Viability in Partially Decellularized Tracheal Grafts

OBJECTIVE

Advancements in tissue-engineered tracheal replacement (TETR) show promise for the use of partially decellularized tracheal grafts (PDTG) to address critical gaps in airway management and reconstruction. In this study, aiming to leverage the immunoprivileged nature of cartilage to preserve tracheal biomechanics, we optimize PDTG for retention of native chondrocytes.

STUDY DESIGN

Comparison in vivo murine study.

SETTING

Research Institute affiliated with Tertiary Pediatric Hospital.

METHODS

PDTG were created per a shortened decellularization protocol using sodium dodecyl sulfate, then biobanked via cryopreservation technique. Decellularization efficiency was characterized by DNA assay and histology. Viability and apoptosis of chondrocytes in preimplanted PDTG and biobanked native trachea (control) was assessed with live/dead and apoptosis assays. PDTG (N = 5) and native trachea (N = 6) were orthotopically implanted in syngeneic recipients for 1-month. At the endpoint, microcomputed tomography (micro-CT) was employed to interrogate graft patency and radiodensity in vivo. Vascularization and epithelialization were qualitatively analyzed using histology images following explant.

RESULTS

PDTG exhibited complete decellularization of all extra-cartilaginous cells and reduced DNA content compared to control. Chondrocyte viability and nonapoptotic cell populations were improved utilizing biobanking and shorter decellularization time. All grafts remained patent. Evaluation of graft radiodensity at 1 month revealed elevation of Hounsfield units in both PDTG and native compared to host, with PDTG showing higher radiodensity than native. PDTG supported complete epithelialization and functional reendothelialization 1-month postimplantation.

CONCLUSION

Optimizing PDTG chondrocyte viability is a key component to successful tracheal replacement. Ongoing research seeks to evaluate the acute and chronic immunogenicity of PDTG.

Cryopreserved Tracheal Grafts: A Review of the Literature

Cryopreserved tracheal grafts have been used in several experimental models of long segment replacement. The clinical application of the procedure has been limited due to the fact that contradictory results have been reported. The purpose of this article is to present a review of the literature on tracheal cryopreservation. Despite the fact that most authors indicate that cryopreserved tracheal allografts retain viability and have a low immunological response, though they continue to function after transplantation with good epithelialization and patency, cryopreservation leads to significant damage to cartilage, the degree of which is based on the freezing-storage methods that affect the function and durability of a graft. The long-term storage of cartilage must therefore be investigated in more detail in basic research models of cartilage viability: the evaluation of chondrocyte apoptosis, and the use of different solutions for tracheal cryopreservation other than RPMI-1640, Dulbecco's modified Eagle's, Eurocollins, and TC-199. Furthermore, problems that involve improving the blood supply to the graft after extensive resection and immunosuppression must be resolved before tracheal cryopreservation can become a clinically established method for tracheal grafts.

Bone morphogenetic protein-2 stimulation of cartilage regeneration in canine tracheal graft

BACKGROUND

Graft stenosis is among the most serious post-surgical complications that can occur after tracheal transplantation. Typically, stenosis is caused by resorption of tracheal cartilage. Bone morphogenetic protein-2 (BMP-2) is efficient at stimulating bone or cartilage regeneration. In this study, BMP-2 is tested for its effects on stimulation of cartilage regeneration in tracheal transplantation.

METHODS

For tracheal autotransplantation, 24 mongrel dogs were divided equally into four groups and BMP-2 was injected between the cartilage rings at doses of 1, 3, 5 or 7 mg. For tracheal allotransplantation, 12 mongrel dogs were divided equally into two groups. One group received 5 mg of BMP-2 per graft, and the other received collagen only as a control. The grafts were harvested after 4 weeks and subjected to pathologic analysis. The diameter of the graft lumen and areas of new cartilage regeneration were measured.

RESULTS

Regenerated cartilage areas were found in both the injected area and around the perichondrium. The areas of regenerated cartilage, as well as the diameter of the tracheal lumen, increased significantly with increasing concentrations of BMP-2. Five milligrams per milliliter was the most effective dose of BMP-2 in this study.

CONCLUSIONS

BMP-2 can significantly stimulate cartilage regeneration in tracheal grafts and also can be used to prevent stenosis after tracheal transplantation.